Indoco Remedies Share Price Rises After Q2 Revenue Grows 7.4% YoY

Mumbai, October 27: Indoco Remedies Limited reported growth in consolidated revenue for the second quarter of FY2026-27, supported by continued business activity across its pharmaceutical operations. The company’s consolidated revenue increased 7.4% year-on-year to ₹471.8 crore from ₹439.3 crore in the corresponding quarter of the previous financial year. The company’s EBITDA stood at ₹46.4 crore, compared with ₹43.1 crore a year earlier. EBITDA as a percentage of net sales improved slightly to 9.2% from 9.1%, according to the company’s earnings announcement.

Indoco Remedies Records H1 Revenue Growth and Margin Improvement in FY2026-27

Indoco Remedies Limited’s financial results for the quarter ended September 30, 2026, showed growth in revenue alongside an improvement in operating earnings. For the first half of FY2026-27, consolidated revenue reached ₹973.1 crore, compared with ₹902.7 crore in the corresponding period last year. EBITDA for the first half increased to ₹87.5 crore from ₹60.6 crore a year earlier. The EBITDA margin improved to 9.0%? The results indicate stronger operating earnings during the first half of the financial year. Investors may also assess the company’s profitability, product portfolio and business performance across domestic and international pharmaceutical markets when evaluating the results.

Stock Market Snapshot

Indoco Remedies share price showed fluctuations during the trading session on October 27, 2026, according to the provided intraday chart. The stock traded around ₹220-₹224 for much of the morning before making a sharp upward move towards approximately ₹236 shortly after 12:45 PM. Following this rise, the share price eased and moved towards ₹228-₹229 near the end of the displayed period. The chart indicates a notable intraday spike followed by partial profit-taking. The exact last traded price and official percentage change are not visible in the screenshot. The price movement alone does not establish that the quarterly results directly caused the change in the stock.

About Indoco Remedies Limited

Indoco Remedies Limited is an Indian pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products. Its operations cover domestic and international markets, supported by manufacturing facilities and research and development capabilities. The company supplies pharmaceutical formulations and other healthcare products across multiple therapeutic categories. Its business performance depends on factors such as product demand, regulatory compliance, manufacturing efficiency and growth across its key markets.

Conclusion

Indoco Remedies reported 7.4% year-on-year growth in consolidated revenue for Q2 FY2026-27, while EBITDA increased to ₹46.4 crore from ₹43.1 crore. First-half revenue and EBITDA also recorded growth compared with the previous year. The company’s operating performance and future financial results will remain important factors for investors assessing its outlook. The stock chart showed a sharp intraday rise followed by a partial retreat, but further market data is required to confirm the session’s final performance.

Source: 

• https://www.nseindia.com/get-quote/equity/INDOCO/Indoco-Remedies-Limited